A phase 1, open label, dose escalation, First-in-Human (FIH) study evaluating the safety, pharmacokinetics, pharmacodynamics and efficacy of AUR 103 in patients with relapsed advanced malignancies (BHARAT-1)

Targeting CD47- SIRPα interaction by novel peptide-based antagonists

Combination efficacy and safety profile of an orally bioavailable small molecule agent targeting CD47/SIRPα axis (CD47 antagonists)

Efficacy and safety profile of AU7R-104, a small molecule targeting CD47/SIRPα pathway

AUR103 an oral small molecule CD47 antagonist in combination with azacytidine and bortezomib exhibits potent anti-tumor activity in myeloma and leukemia models in vitro and in